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ABSTRACT 
Background: Cognitive dysfunction occurs in depression and can persist into 
remission.  It impacts on patient functioning but remains largely unrecognised, 
unmonitored and untreated.  We explored understanding of cognitive dysfunction in 
depression among UK clinicians. 
Methods: A multi-step consultation process.  Step 1: a multi-stakeholder steering 
committee identified key themes of burden, detection and management of cognitive 
dysfunction in depression, and developed statements on each to explore understanding 
and degree of agreement among clinicians.  Step 2: 100 general practitioners (GPs) 
and 100 psychiatrists indicated their level of agreement with these statements.  Step 3: 
the steering committee reviewed responses and highlighted priority areas for future 
education and research. 
Results: There was agreement that clinicians are not fully aware of cognitive 
dysfunction in depression.  Views of the relationship between cognitive dysfunction 
and other depressive symptom severities was not consistent with the literature.  In 
particular, there was a lack of recognition that some cognitive dysfunction can persist 
into remission.  There was understandable uncertainty around treatment options, given 
the current limited evidence base.  However, it was recognised that cognitive 
dysfunction is an area of unmet need and that there is a lack of objective tests of 
cognition appropriate for depressed patients that can be easily implemented in the 
clinic. 
Limitations: Respondents are likely to be ‘led’ by the direction of the statements they 
reviewed.  The study did not involve patients and carers. 
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Conclusions: UK clinicians should undergo training regarding cognitive dysfunction 
in depression, and further research is needed into its assessment, treatment and 
monitoring. 
 
Keywords: 
Cognitive dysfunction 
Depression 
Clinician awareness 
4 
Abbreviations: GP, general practitioner; HCP, health-care professional 
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1.  Introduction 
Cognitive dysfunction is an important aspect of depression that includes problems 
with thinking, concentration and memory (American Psychiatric Association, 2013; 
Hammar and Årdal, 2009).  Cognitive dysfunction is highly prevalent in people with 
depression and has a significant impact on functioning (Jaeger et al., 2006; McIntyre 
et al., 2013; Shilyansky et al., 2016).  In a recent, cross-sectional, observational study 
in South Korea, greater functional disability and impairment in daily activities, 
including worse work-related productivity outcomes, were associated with more 
severe perceived cognitive dysfunction (Kim et al., 2016).  The domains of executive 
function, working memory, episodic memory, attention and psychomotor processing 
speed are commonly affected in people with depression (McIntyre et al., 2013; 
Shilyansky et al., 2016), with poorer performance in neuropsychological tests being in 
the order of small (0.2) to medium (0.5) effect sizes compared to healthy individuals 
(Lee et al., 2012).  Cognitive problems may also remain as residual symptoms during 
periods of remission from major depressive episodes (Conradi et al., 2011; 
McClintock et al., 2011), with residual symptoms increasing the risk of relapse (Judd 
et al., 1998).  In a systematic review and meta-analysis of cognitive function, 
significant moderate deficits in executive function and attention (effect sizes ranging 
from -0.52 to -0.61) were found to persist in patients in whom depressive symptoms 
had remitted (Rock et al., 2014).  This has been confirmed in a recent, large (n = >700 
completers), randomised trial of three antidepressants (escitalopram, sertraline and 
venlafaxine), which showed that even in patients whose depression remitted with 
treatment, there was no significant improvement in cognition, which remained 
impaired compared to matched healthy control individuals (Shilyansky et al., 2016).  
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It has been suggested that cognitive dysfunction in depression is largely unrecognised 
and unmonitored by clinicians (Greer et al., 2010). 
We aimed to explore the understanding of aspects of cognitive dysfunction in clinical 
depression (major depressive disorder) in the UK, using a multi-step consultation 
process involving primary and secondary care clinicians with an interest in 
depression.  It was intended that through this process, priority areas to be addressed 
through education would be highlighted. 
2.  Methods 
Using a multi-step process, we obtained and evaluated the views of primary and 
secondary care experts in depression.  In Step 1, a multi-stakeholder steering 
committee (including eight psychiatrists, psychologists, primary care physicians, and 
representatives from occupational therapy and a depression charity) provided the three 
key themes, which were burden, detection and management of cognitive dysfunction 
in depression.  Through round-table discussion, the steering committee developed 
~10–15 statements for each of these areas to explore the understanding of clinicians 
and the level of agreement among them. 
In Step 2, these statements formed an online survey (hosted by medeConnect, part of 
Doctors.net.uk) completed by 200 health-care professionals (HCPs) (100 general 
practitioners [GPs] and 100 psychiatrists) with an involvement in the management of 
depression in the UK.  In order to be included on the HCP panel, participants had to 
have seen or treated a minimum number of patients with major depressive disorder in 
the previous 3 months: GPs ≥10 patients; psychiatrists ≥20 patients.  Participants were 
asked to rate their level of agreement with the statements as “strongly disagree”, 
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“disagree”, “agree”, “strongly agree” or “don’t know/uncertain”.  Participants also 
had the ability to add free-text comments to expand on their responses.  The level of 
agreement among respondents was defined by the steering committee as follows: 
High agreement, >66% of respondents; Very high agreement, >90% of respondents. 
In Step 3, the steering committee reviewed feedback from Step 2 and highlighted 
priority areas for future education and research. 
3.  Results 
A total of 200 respondents from across the UK completed the questionnaire (Table 1).  
In addition to rating the proposed statements, some respondents provided specific 
comments (Supplementary Table S1).  Overall, there was High/Very high agreement 
among GPs and psychiatrists for 10 of 13 statements related to burden of cognitive 
dysfunction in depression, seven of nine statements on detection and seven of 
12 statements on management. 
3.1.  Burden 
There was High/Very high agreement from both GPs and psychiatrists for all except 
three of the statements related to burden of cognitive dysfunction in depression 
(Fig. 1).  This suggested that both GPs and psychiatrists recognise that cognitive 
dysfunction occurs in depression and can have a significant impact on a patient’s life, 
impairing a person’s occupational, social, marital and parental functioning, and 
reducing their confidence.  Additionally, clinicians agreed that cognitive dysfunction 
contributes to an overall increased economic and social burden of depression on the 
individual, their family and society as a whole.  These views are illustrated by one 
psychiatrist who commented, “In clinical practice, I have seen the impact of cognitive 
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dysfunction on patients’ lives and rightly so, it is disabling”.  There was also 
agreement that more research into the burden of cognitive dysfunction in depression is 
required. 
However, there was less agreement among clinicians regarding the persistence of 
cognitive dysfunction and the relationship with depressive symptoms, with views 
being inconsistent with the evidence that cognitive dysfunction persists into 
remission, at least in some patients (Rock et al., 2014; Shilyansky et al., 2016).  Low 
agreement (≤50% agreement) was reached on Statement 2 (Cognitive dysfunction in 
depression is independent of depressive symptoms); 50% of GPs and 57% of 
psychiatrists disagreed with this statement, with GP comments including, “How can 
you have cognitive dysfunction in depression without depression?” and “I’ve found 
some patients with “chronic depression” often have associated impaired or reduced 
cognitive function.  I don’t know which causes which”.  Similarly, only 40% of GPs 
and 54% of psychiatrists agreed with Statement 11 (More than 30% of patients 
experience persistent cognitive symptoms despite remission of depressive symptoms).  
Individual comments included, “I associated cognitive dysfunction with the 
depressive illness but generally expect this to be restored once the patient has 
recovered from depression”, “Usually cognitive function improves in my patients, 
though not necessarily right at the outset of the improvement in mood” and “I don’t 
routinely see cognitive dysfunction persisting after symptomatic remission.  If I did, 
I’d be investigating them for an independent cognitive problem”. 
Despite High agreement from psychiatrists, only 52% of GPs agreed with Statement 
12 (Recovery of cognitive function is less likely following repeated episodes of 
depression). 
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3.2.  Detection 
There was High/Very high agreement from both GPs and psychiatrists for seven of 
the nine statements (Fig. 2).  Despite the responses above, there was also agreement 
that a lack of awareness of cognitive dysfunction in depression among clinicians is an 
issue.  Additionally, there was high agreement between psychiatrists that cognitive 
dysfunction is poorly understood (79%), and almost two-thirds of GPs (62%) agreed 
with Statement 15 (Cognitive dysfunction in depression is poorly understood by 
health-care professionals).  Despite Very high agreement from psychiatrists, over half 
of the GPs (54%) also disagreed that Cognitive dysfunction in depression is more 
likely to be detected in secondary care (e.g. by psychiatrists) than in primary care 
(e.g. by GPs).  There was high agreement among all clinicians that cognitive 
dysfunction in depression remains an unmet need and that there is a lack of available 
tools to detect it, with it usually being assessed simply subjectively.  As a GP 
commented, “I often diagnose depression in patients with memory impairment or 
other cognitive difficulties.  This is largely based on history rather than a formal 
objective assessment”.  Concerns raised by psychiatrists included, “There are no 
systematic ways of assessing cognitive function other than referral for 
neuropsychology testing, which is not feasible given current resources”.  Clinicians 
felt that routine assessment of cognition should be available and that research is 
needed to assess the cost-effectiveness of such screening.  Finally, there was Very 
high agreement among both GPs and psychiatrists that depression should be 
considered as a possible diagnosis in elderly patients presenting with mild cognitive 
dysfunction. 
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3.3.  Management 
Management of cognitive dysfunction in depression was the area of biggest 
disagreement among clinicians, perhaps not surprisingly.  There was High/Very high 
agreement from GPs and/or psychiatrists for just seven of the 12 statements (Fig. 3).  
Overall, there was high agreement that there is uncertainty around best practice for the 
management of cognitive dysfunction.  This was consistent with the responses to 
Statements 24, 25, 26 and 27, which related to the evidence for the effects of 
cognitive behavioural therapy, cognitive training/behavioural activation, exercise or 
lifestyle changes on cognitive function in depression, respectively, with 28–51% of 
clinicians responding “Don’t know/uncertain”.  With regard to Statement 28 
(Improvement in cognitive dysfunction does not occur with all antidepressants), 60% 
of GPs and 65% of psychiatrists agreed, and there was High agreement among 
psychiatrists, though not quite with GPs, that recovery of cognitive function does not 
always occur despite clinical recovery from depression (Statement 31), in line with 
the evidence (Shilyansky et al., 2016) but not entirely consistent with clinicians’ 
earlier responses to the statements on burden of cognitive dysfunction.  Nevertheless, 
there was High agreement among all clinicians that persistent cognitive dysfunction 
may be a risk factor for relapse.  There was High agreement that research into the 
effects of antidepressants on cognitive dysfunction should be prioritised, and that the 
degree of dysfunction should be monitored during long-term follow-up and after 
antidepressants are discontinued. 
4.  Discussion 
This report provides insight into the level of understanding of cognitive dysfunction in 
depression by GPs and psychiatrists in the UK.  Responses of clinicians to the 
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statements they were presented with identify a number of areas that need to be 
addressed in the education of clinicians and/or in research. 
While there was High agreement among both GPs and psychiatrists that they 
recognised cognitive dysfunction in depression and its implications for individuals 
and society, a concern is that this was simply due to them, in effect, answering leading 
questions, since they also appear to hold the view that clinicians in general are 
unaware of this issue.  If this latter perspective is correct, then there is a clearly 
identified educational need for clinicians – both GPs and psychiatrists – regarding the 
presence and nature of cognitive dysfunction in depression.  Appropriate continuing 
professional development materials should be made available to address the 
limitations in clinician knowledge and it would be advantageous for GPs and 
psychiatrists to learn together, allowing both groups to benefit from each other’s 
perspective and different clinical insights and experiences. 
Perhaps one of the clearest findings, reflected in the response to a number of 
statements, is that there is either uncertainty regarding the relationship between 
depressive symptom severity and cognitive dysfunction, or a belief that when 
symptoms such as low mood resolve, so does cognitive dysfunction.  While the 
wording of Statement 2 (Cognitive dysfunction in depression is independent of 
depressive symptoms) was potentially ambiguous in the way it could have been 
interpreted by the clinician panel, evidence from the largest single study in the 
literature suggests that the severity of the depression and of the cognitive dysfunction 
are not correlated (Shilyansky et al., 2016).  Cognitive dysfunction may be long 
lasting after symptom recovery, at least in some patients (Hammar and Årdal, 2009; 
Rock et al., 2014).  Additionally, cognitive dysfunction may pre-date the appearance 
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of mood symptoms (Foland-Ross and Gotlib, 2012), with a study of 708 non-
depressed individuals highlighting that low episodic memory performance constituted 
a risk of depression diagnosis 3 years later (Airaksinen et al., 2007).  Similarly, 
despite the uncertain responses to Statement 11 by both GPs and psychiatrists (More 
than 30% of patients experience persistent cognitive symptoms despite remission of 
depressive symptoms), there is clear evidence from a number of studies that cognitive 
dysfunction persists into remission for significant numbers of patients (Conradi et al., 
2011; Jaeger et al., 2006; McIntyre et al., 2013).  For example, in a 3-year prospective 
study of 267 primary care patients, cognitive impairment was present ~94% of the 
time during depressive episodes and 44% of the time during periods of remission 
(Conradi et al., 2011).  Furthermore, recurrent depression has increased detrimental 
effects on cognitive ability (Baune et al., 2010).  Indeed, psychiatrists were more 
inclined to recognise that recovery of cognitive function is less likely following 
repeated episodes of depression than GPs, perhaps as a result of differences in how 
GPs and psychiatrists follow up patients. 
There was agreement among both GPs and psychiatrists that cognitive dysfunction in 
depression is an unmet need and an acknowledgement that more research is required, 
in relation to both the nature and treatment of the dysfunction.  How much this 
resulted from clinicians being prompted in this direction by the statements is 
uncertain. 
GPs and psychiatrists appeared to have differing views on whether cognitive 
dysfunction is more likely to be detected in primary or secondary care, which is 
perhaps not surprising given the potential for response bias inherent in the wording of 
this particular statement, but, overall, both groups agreed that this remains an area of 
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unmet need and there is a lack of readily available tools for assessment and 
monitoring of cognition.  Specific comments from GP and psychiatrist participants 
included the following: “It’s under-recognised and difficult to measure”, “Although 
poor concentration is a core symptom of depression which is often enquired about, 
other cognitive domains are not commonly tested for/addressed” and “Validated tools 
for use in primary care would be useful in assessing/detecting and then monitoring 
cognitive function.  The only tools we have are designed primarily for dementia-
related illness”. 
Instruments exist to assess the level of cognitive impairment in patients with dementia 
(e.g. Cambridge Cognitive Examination, Mini Mental State Examination); however, 
these are not fully validated for use in patients with depression.  Although subjective 
assessments are available, such as patient-reported questionnaires, and simple 
questions on daily function may be asked by the physician, these do not provide as 
full a picture of cognitive function as more comprehensive objective testing.  
Furthermore, there is evidence of a lack of correlation between subjective and 
objective assessment of cognition in patients with depression (Svendsen et al., 2012).  
Ideally, the cognitive function of a patient with depression would be assessed shortly 
after diagnosis, both subjectively and objectively, and this would subsequently be 
monitored during the course of treatment. 
At present, there is a clinical tool under development that may address some of these 
points.  The THINC-it tool is quick and easy to use and combines objective and 
subjective measures.  It is capable of identifying cognitive dysfunction in primary and 
secondary care (McIntyre, 2015).  The tool is currently being validated in a large, 
real-world study. 
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A few of the individual comments (Supplementary Table S1) suggested that some 
doctors were unsure if routine cognitive assessment was appropriate, as tests may be 
too strenuous and detrimental to a patient’s confidence.  However, the opposite view 
may also apply, such that patients are reassured that cognitive impairment identified 
by the tests is something that is common in depression. 
Almost all respondents agreed that depression should be considered as a possible 
diagnosis in older patients with mild cognitive problems, which may mean that recent 
educational initiatives on this topic in the UK have been successful.  One GP noted, 
“In early dementia, MDD has high prevalence”. 
Uncertainty regarding the role of routine assessment of cognitive assessment in 
depression is further compounded by uncertainty about its best-practice management.  
Respondents agreed that there is uncertainty about the best-practice management of 
cognitive dysfunction in patients with depression, which was also apparent in the 
mixed responses to several of the statements on this topic.  The widespread 
uncertainty among both GPs and psychiatrists about some psychological therapies 
may be a consequence of a genuine lack of knowledge and/or the low quality of 
studies in this area, such as the lack of placebo-controlled trials.  It was concluded 
from a meta-analysis of cognitive bias modification interventions in anxiety and 
depression that effects may be small and not clinically relevant, and that trials are 
small and of low quality (Cristea et al., 2015).  In addition, publication bias was raised 
as an issue and it was highlighted that many positive outcomes are driven by extreme 
outliers (Cristea et al., 2015).  Stronger evidence is available on the use of cognitive 
behavioural therapy for the treatment of depression, and a recent meta-analysis 
considered comparative benefits/harms of cognitive behavioural therapies and second-
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generation antidepressants in initial treatment of major depressive disorder (Amick et 
al., 2015).  Studies on the effects of antidepressants on cognitive dysfunction in 
depression have also had limitations, with early studies often including only small 
numbers of patients, not having cognitive function as a primary end point, lacking a 
placebo control or being restricted to elderly patients.  One psychiatrist noted, “In the 
absence of evidenced treatments, assessments (even if they were available) are 
difficult to prioritise.  Which is a shame”. 
5.  Limitations 
The statements were reviewed by a relatively small sample size of 200 UK-only 
respondents and no formal statistical analysis was performed on the results.  A full 
Delphi process for gaining consensus was not employed.  By their very nature, 
statements may lead clinicians, with them perhaps being more likely to agree than 
disagree.  Overall, there were far more “agree” answers than “disagree” or even 
“don’t know” responses.  Furthermore, since the survey instrument had not been 
empirically validated, there may have been significant variability in how individual 
respondents interpreted the meaning of the statements.  Respondents were required to 
have seen or treated a minimum number of patients with major depressive disorder in 
the previous 3 months but no information on patient age was collected.  The study did 
not involve patients and carers, who may hold very different perspectives on the topic. 
6.  Conclusions 
Overall, these responses from UK GPs and psychiatrists support the notion that UK 
clinicians should undergo training regarding the presence and nature of cognitive 
dysfunction in depression, and its relationship to other depressive symptoms.  There is 
16 
a need for tools to facilitate the objective assessment of cognition that can be easily 
used in the clinic, both in primary and secondary care, and education of clinicians 
regarding the use of such tools.  Ongoing research is needed regarding possible 
treatments for cognitive dysfunction, both physical treatments such as drugs and 
psychological treatments.  The arrival of effective treatments will also lead to the need 
for research into the cost-effectiveness of screening patients with depression for 
cognitive dysfunction. 
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Table 1 
Role and geographical location of HCP panel. 
 GPs Psychiatrists 
Role   
Seniority GP, % 
     GP partner/Principal 
     Salaried GP 
 
78 
22 
 
GP with special interest in mental health, % 26  
Seniority psychiatrist, % 
     Consultant 
     Associate specialist 
     Staff grade 
     Specialist registrar 4 
  
79 
7 
7 
7 
21 
Psychiatry sub-speciality, % 
     General adult psychiatrist 
     Old age psychiatrist 
  
73 
27 
Mean major depressive disorder caseload in previous 3 months, n 43 64 
Region, n   
North West 11 9 
North East 4 4 
Yorks and Humber 8 4 
East Midlands 7 6 
West Midlands 8 7 
Eastern England 9 7 
London 13 19 
South East Coastal 7 11 
22 
South Central 6 7 
South West 9 6 
Scotland 10 8 
Wales 5 5 
Northern Ireland 3 7 
Abbreviations: HCP, health-care practitioner; GP, general practitioner. 
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Supplementary Table S1 
Individual comments received from GPs and psychiatrists. 
GP comments Psychiatrist comments 
Burden  
Further research in every aspect of clinical 
medicine is always a welcome development 
In older adults, it can be difficult to 
distinguish between cognitive dysfunction in 
depression and cognitive impairment 
How can you have cognitive dysfunction in 
depression without depression? 
In clinical practice, I have seen the impact of 
cognitive dysfunction on patients’ lives and 
rightly so, it is disabling 
I think this is poorly recognised especially if 
we just use the PHQ9 as a scoring tool 
without looking at the individual responses 
I don’t routinely see cognitive dysfunction 
persisting after symptomatic remission.  If I 
did, I’d be investigating them for an 
independent cognitive problem 
Usually cognitive function improves in my 
patients, though not necessarily right at the 
outset of the improvement in mood 
Sometimes the cognitive dysfunction seen in 
depression may be a precursor symptom of 
underlying dementia 
I associated cognitive dysfunction with the 
depressive illness but generally expect this to 
be restored once the patient has recovered 
from depression 
Frequently, elderly individuals are referred 
by their GP for assessment of poor memory, 
which, after full assessment, is found to be 
secondary to depression.  Following adequate 
treatment, there usually appears to be a 
complete resolution of cognitive impairment, 
although social functioning can take longer to 
improve 
24 
Loneliness is the most significant aetiological 
factor for both cognitive dysfunction and 
depression 
It’s under-recognised and difficult to measure 
Most antidepressants don’t directly improve 
cognition.  I think it would be useful for trials 
to look at the effect of antidepressants on 
cognitive function specifically, as well as 
changes in mood.  I am not aware of any such 
data.  I think this would be key in deciding 
what agent to use in certain cases 
It’s difficult to say that there are persistent 
cognitive symptoms after remission of 
depression.  There is gradual recovery even 
in case of severe depression, though some 
patients have memory lapse of the acute 
episode 
It’s the Cinderella of medicine mental health  
Detection  
Most patients over the age of 55 years have 
multiple co-morbidities, which often cause 
depression and reduced cognitive function 
It is worth investigating for dementia in older 
patients presenting with cognitive impairment 
and depression for the first time 
It’s a sapping process dealing with mental 
health and we haven’t the time as primary 
care physicians 
There are no systematic ways of assessing 
cognitive function other than referral for 
neuropsychology testing, which is not 
feasible given current resources 
No.  I’m aware of cognitive dysfunction in 
depression as part of symptoms depression 
may present with; the PHQ9 score doesn’t 
really assess this 
More questionnaires won’t help patients – 
especially when there is cognitive 
impairment.  I am sceptical of forcing 
cognitive dysfunction into the limelight to 
create a marketing niche 
25 
Although it is subjective and not really 
formally assessed, it is common sense and the 
symptoms tie in with depression although 
other causes need to be excluded also 
There is good understanding of cognitive 
dysfunction by secondary care professionals 
(some health-care support staff do not 
understand and need some education about 
it).  Patients and relatives express concerns 
about cognitive dysfunction 
In early dementia, MDD has high prevalence Cognitive symptoms often go unrecognised 
Do have screening tools available but don’t 
concentrate just on cognitive function.  Also 
am limited with what I can do in a 10-minute 
consultation 
We need access to good-quality screening 
and in-depth assessment tools 
I often diagnose depression in patients with 
memory impairment or other cognitive 
difficulties.  This is largely based on history 
rather than a formal objective assessment 
I am not convinced that routine cognitive 
assessment is appropriate for all patients with 
depression: existing tools may be too 
complex/strenuous.  Sometimes, it is also 
more beneficial to await the resolution of 
depressive symptoms to avoid denting a 
patient’s confidence when it is already fragile 
Is clearly linked in older people with 
depression – but are we forgetting it in the 
younger severely depressed population? 
 
Depression can have subtle or no 
psychological symptoms 
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Management  
I’ve found some patients with “chronic 
depression” often have associated impaired 
or reduced cognitive function.  I don’t know 
which causes which 
Although poor concentration is a core 
symptom of depression which is often 
enquired about, other cognitive domains are 
not commonly tested for/addressed 
Validated tools for use in primary care would 
be useful in assessing/detecting and then 
monitoring cognitive function.  The only 
tools we have are designed primary for 
dementia-related illness 
I would like to learn more about the evidence 
about exercise, lifestyle changes, etc.  This is 
an area that needs to be focused on more in 
clinical practice to improve the quality of life 
of the patients 
The combination of CBT with 
antidepressants tend to work for most 
patients; however, there is a need to reassess 
cognitive dysfunction at least twice a year for 
patients with major depressive disorder 
Cognitive function should be reassessed 
following improvement of depressive 
symptoms.  If impairment persists should 
investigate further for dementia 
These patients will usually be under the care 
of the community psychiatry team.  In my 
area there does not seem to be much 
communication regarding cognitive 
dysfunction in these patients, certainly not 
longer-term monitoring 
The effects of lifestyle, behavioural 
activation, exercise, etc are mediated by 
improvement in depression and therefore 
concentration.  Formal testing is either blunt 
(bedside – MoCA/MMSE, etc) or extremely 
expensive, with a waiting list longer than the 
average episode of depression.  The 
important thing is finding out whether the 
concentration and memory problems are 
affecting ability to drive, work, care or parent 
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In general practice, we do not have the luxury 
of following up a patient 4–6 months after 
they have ceased taking antidepressants 
In the absence of evidenced treatments, 
assessments (even if they were available) are 
difficult to prioritise.  Which is a shame 
Although exercise or cognitive training and 
CBT may help with depression, I am 
uncertain of the evidence in relation to these 
There is role for functional neuroimaging too 
in establishing the link between depression 
and cognitive deficits 
Abbreviations: GP, general practitioner; PHQ9, Patient Health Questionnaire; 
MDD, major depressive disorder; CBT, cognitive behavioural therapy; 
MoCA, Montreal Cognitive Assessment; MMSE, Mini Mental State Examination. 
28 
Figure legends 
Fig. 1.  Statements on burden of cognitive dysfunction in depression (A) and 
responses (B). 
Abbreviations: GP, general practitioner; Psych, psychiatrist. 
Fig. 2.  Statements on detection of cognitive dysfunction in depression (A) and 
responses (B). 
Abbreviations: GP, general practitioner; Psych, psychiatrist. 
Fig. 3.  Statements on management of cognitive dysfunction in depression (A) and 
responses (B). 
Abbreviations: GP, general practitioner; Psych, psychiatrist. 
 
